Literature DB >> 35083503

Diffusion and perfusion imaging biomarkers of H3 K27M mutation status in diffuse midline gliomas.

Nihar Kathrani1, Richa Singh Chauhan2, Abhishek Kotwal2, Karthik Kulanthaivelu2, Maya Dattatraya Bhat3,4, Jitender Saini2, Chandrajit Prasad2, Dhritiman Chakrabarti5, Vani Santosh6, Alok Mohan Uppar7, Dwarakanath Srinivas7.   

Abstract

PURPOSE: H3K27M-mutant diffuse midline gliomas (M-DMGs) exhibit a clinically aggressive course. We studied diffusion-weighted imaging (DWI) and perfusion (PWI) MRI features of DMG with the hypothesis that DWI-PWI metrics can serve as biomarkers for the prediction of the H3K27M mutation status in DMGs.
METHODS: A retrospective review of the institutional database (imaging and histopathology) of patients with DMG (July 2016 to July 2020) was performed. Tumoral apparent diffusion coefficient (ADC) and peritumoral ADC (PT ADC) values and their normalized values (nADC and nPT ADC) were computed. Perfusion data were analyzed with manual arterial input function (AIF) and leakage correction (LC) Boxerman-Weiskoff models. Normalized maximum relative CBV (rCBV) was evaluated. Intergroup analysis of the imaging variables was done between M-DMGs and wild-type (WT-DMGs) groups.
RESULTS: Ninety-four cases (M-DMGs-n = 48 (51%) and WT-DMGs-n = 46(49%)) were included. Significantly lower PT ADC (mutant-1.1 ± 0.33, WT-1.23 ± 0.34; P = 0.033) and nPT ADC (mutant-1.64 ± 0.48, WT-1.83 ± 0.54; P = 0.040) were noted in the M-DMGs. The rCBV (mutant-25.17 ± 27.76, WT-13.73 ± 14.83; P = 0.018) and nrCBV (mutant-3.44 ± 2.16, WT-2.39 ± 1.25; P = 0.049) were significantly higher in the M-DMGs group. Among thalamic DMGs, the min ADC, PT ADC, and nADC and nPT ADC were lower in M-DMGs while nrCBV (corrected and uncorrected) was significantly higher. Receiver operator characteristic curve analysis demonstrated that PT ADC (cut-off-1.245), nPT ADC (cut-off-1.853), and nrCBV (cut-off-1.83) were significant independent predictors of H3K27M mutational status in DMGs.
CONCLUSION: DWI and PWI features hold value in preoperative prediction of H3K27M-mutation status in DMGs.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Diffuse midline glioma; H3K27M; MRI

Mesh:

Substances:

Year:  2022        PMID: 35083503     DOI: 10.1007/s00234-021-02857-x

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.995


  4 in total

1.  cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.

Authors:  David N Louis; Caterina Giannini; David Capper; Werner Paulus; Dominique Figarella-Branger; M Beatriz Lopes; Tracy T Batchelor; J Gregory Cairncross; Martin van den Bent; Wolfgang Wick; Pieter Wesseling
Journal:  Acta Neuropathol       Date:  2018-03-01       Impact factor: 17.088

2.  Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.

Authors:  J L Boxerman; K M Schmainda; R M Weisskoff
Journal:  AJNR Am J Neuroradiol       Date:  2006-04       Impact factor: 3.825

3.  Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.

Authors:  Karisa C Schreck; Surabhi Ranjan; Nebojša Skorupan; Chetan Bettegowda; Charles G Eberhart; Heather M Ames; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2019-03-12       Impact factor: 4.130

4.  Use of Preoperative Apparent Diffusion Coefficients to Predict Brain Tumor Grade.

Authors:  Aneela Darbar; Muhammad Waqas; Syed Faaiz Enam; Shaikh D Mahmood
Journal:  Cureus       Date:  2018-03-07
  4 in total
  1 in total

1.  Multiparametric MRI-Based Radiomics Model for Predicting H3 K27M Mutant Status in Diffuse Midline Glioma: A Comparative Study Across Different Sequences and Machine Learning Techniques.

Authors:  Wei Guo; Dejun She; Zhen Xing; Xiang Lin; Feng Wang; Yang Song; Dairong Cao
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.